盘龙药业: 信息披露管理制度

Core Viewpoint - The document outlines the information disclosure management system of Shaanxi Panlong Pharmaceutical Group Co., Ltd, emphasizing the importance of timely, accurate, and complete information disclosure to protect the rights of investors and comply with relevant laws and regulations. Group 1: General Principles - The company aims to ensure that all disclosed information is true, accurate, complete, timely, and fair, without any false records or misleading statements [3][4][5] - Information disclosure obligations apply to the company, its directors, senior management, and other relevant parties, ensuring that significant events affecting stock prices are disclosed promptly [2][6] Group 2: Disclosure Procedures - The company must disclose periodic reports, including annual and interim reports, which should be audited by qualified accounting firms [10][21] - The disclosure of significant events must occur immediately when they are known, especially if they could impact stock prices [18][22] Group 3: Responsibilities and Oversight - The board of directors is responsible for establishing and implementing the information disclosure management system, ensuring compliance and timely disclosures [15][19] - The audit committee and independent directors are tasked with supervising the implementation of the disclosure system and addressing any deficiencies [8][29] Group 4: Specific Disclosure Requirements - The company must disclose information regarding major shareholders, changes in control, and any significant legal proceedings that could affect its financial status [20][34] - Any changes in the company's financial performance or significant operational events must be reported to maintain transparency with investors [14][16]